| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/23/2003 | WO2003006438A1 Benzimidazole derivatives for treating microglia-activation associated diseases such as inflammatory, allergic, infectious or autoimmune diseases |
| 01/23/2003 | WO2003006436A1 Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides |
| 01/23/2003 | WO2003006425A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006424A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006071A1 Infection control system |
| 01/23/2003 | WO2003006062A1 Pharmaceutical agents containing acyclovir, fusaric acid and derivatives thereof |
| 01/23/2003 | WO2003006048A1 Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds |
| 01/23/2003 | WO2003006017A2 Use of certain castanospermine esters in the treatment of influenza virus infections |
| 01/23/2003 | WO2003005971A2 Tetracycline compounds having target therapeutic activities |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2003005957A2 Mutants of clostridium septicum alpha toxin and vaccines, antibodies, sera, and methods of treatment therewith |
| 01/23/2003 | WO2003005952A2 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 01/23/2003 | WO2002072827A9 Traf3-binding b cell-specific receptor |
| 01/23/2003 | WO2002070002A9 Methods for regulation of immune responses to conditions involving mediator-induced pathology |
| 01/23/2003 | WO2002067984A9 Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection |
| 01/23/2003 | WO2002060468A3 Antiviral activities of primate theta defensins and mammalian cathelicidins |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002055015A3 Rapid antibiotic susceptibility test |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002048388A9 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002045570A3 Methods and compositions for the diagnosis and treatment of viral disease using 55092 |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002029413A3 An assay for rhabdovirus inhibitors |
| 01/23/2003 | WO2002020773A3 Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002018585A3 Packaging of positive-strand rna virus replicon particles |
| 01/23/2003 | WO2002015661A3 Inhibitors of hiv replication and method of treatment of hiv infections |
| 01/23/2003 | WO2002011761A3 Vaccine against rsv |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002006513A3 A method for treating herpes viruses |
| 01/23/2003 | WO2002002607A3 Acid-modified arabinogalactan protein composition |
| 01/23/2003 | WO2001089364A3 Hcv variants |
| 01/23/2003 | WO2001063280A3 Inter-alpha-trypsin as a marker for sepsis |
| 01/23/2003 | US20030018197 Administering a therapeutically effective amount of a pyrrazole sulfide or ether compound to treat the human immunodeficiency virus infection |
| 01/23/2003 | US20030018189 Cyclic polyamines having total 9-24 members which have activity in against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors |
| 01/23/2003 | US20030018186 Monocyclic L-nucleosides, analogs and uses thereof |
| 01/23/2003 | US20030018165 Uses of suppressive macrophage activation factors |
| 01/23/2003 | US20030018074 Antiinflammatory agents; skin disorders; topical applying |
| 01/23/2003 | US20030018049 Azithromycin combination for emesis control in mammals |
| 01/23/2003 | US20030018046 Chemokine receptor binding heterocyclic compounds |
| 01/23/2003 | US20030018040 Tumor necrosis factor antagonist; side effect reduction;antiinflammatory agents |
| 01/23/2003 | US20030018039 Viricides |
| 01/23/2003 | US20030018013 Cardiovascular disorders; antilipemic agents; Alzheimer's disease |
| 01/23/2003 | US20030018005 Autoimmune disease; antiinflammatory agents; antiallergens; rheumatic diseases; antitumor agents |
| 01/23/2003 | US20030017975 Immunosuppressants; activation of lipopeptide fungicides |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017586 Nucleotide sequences coding polypeptide for use in the treatment of viral diseases |
| 01/23/2003 | US20030017570 Chitinase materials and methods |
| 01/23/2003 | US20030017562 Nucleotide sequences coding polypetide for use in the treatment, prevention and diagnosis of gastrointestinal and apoptosis disorders |
| 01/23/2003 | US20030017532 ndp |
| 01/23/2003 | US20030017520 High-efficiency assay for protein mannosyl transferases |
| 01/23/2003 | US20030017495 Enterococcus faecalis polynucleotides and polypeptides |
| 01/23/2003 | US20030017450 Detection of viral nucleotide sequences in sample; obtain sample, denature, incubate with pimers, hybridize, amplify, expose to probe, detect signal presence indicates viral nucleotide sequences |
| 01/23/2003 | US20030017448 Preventing uterine infection of fetuses; obtain swine, administer antibodies, monitor swine births for infected fetus, no infection indicates preventive antibody |
| 01/23/2003 | US20030017207 Compositions and methods for treating vulvovaginitis and vaginosis |
| 01/23/2003 | US20030017200 Oral administration of terbinafine, a buffering component and a disintegrant; fungicides |
| 01/23/2003 | US20030017174 Containing herpes simplex virus VP22 polypeptides capable of eliciting a cellular immune response |
| 01/23/2003 | US20030017172 Feline polynucleotide vaccine formula |
| 01/23/2003 | US20030017171 Also contains an antigen of swine influenza virus, porcine reproductive and respiratory syndrome virus, or porcine circovirus; an acrylic acid polymer, metabolizable oil and an oxyethylene-oxypropylene block polymer as adjuvant |
| 01/23/2003 | US20030017162 Preventing and treating Gram-negative sepsis. |
| 01/23/2003 | US20030017156 Immunogenic polypeptide |
| 01/23/2003 | US20030017155 Treating a condition characterized by activation of the inflammatory cytokine cascade |
| 01/23/2003 | US20030017153 Determining whether a patient's immune system can be modified through stimulation of thymus function; sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. |
| 01/23/2003 | US20030017151 Receptor Activator of NF-kappa B antagonists; treatment of medical conditions that require the formation of new bone. |
| 01/23/2003 | US20030017145 Treating subjects suffering from herpes virus infections, acquired immunodeficiency syndrome, and hepatitis C infections by administering a compound effective to inhibit the production or release of the ROMs. |
| 01/23/2003 | US20030017120 Delivery of erectile dysfunction drugs through an inhalation route |
| 01/23/2003 | US20030017119 Aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not heroin; opiods include morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, etc. |
| 01/23/2003 | US20030017118 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 01/23/2003 | US20030017117 Delivery of analgesics through an inhalation route |
| 01/23/2003 | US20030017116 Delivery of sedative-hypnotics through an inhalation route |
| 01/23/2003 | US20030017115 Aerosol comprises particles comprising at least 10 percent by weight of a drug ester. |
| 01/23/2003 | US20030017114 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. |
| 01/23/2003 | US20030015190 Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/23/2003 | US20030015189 Delivery of antihistamines through an inhalation route |
| 01/23/2003 | CA2707767A1 Biologically active peptides |
| 01/23/2003 | CA2453531A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453187A1 Production of transduced hematopoietic progenitor cells |
| 01/23/2003 | CA2453183A1 In vivo production of small interfering rnas that mediate gene silencing |
| 01/23/2003 | CA2453182A1 Crystalline thiazine oxazolidinones |
| 01/23/2003 | CA2452630A1 Use of oxidised lipoproteins for differentiation of precursor cells into mature dendritic cells |
| 01/23/2003 | CA2452582A1 G-csf conjugates |
| 01/23/2003 | CA2452513A1 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound |
| 01/23/2003 | CA2452491A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | CA2452417A1 Compositions comprising the biologicially active peptide ysl |
| 01/23/2003 | CA2452382A1 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 01/23/2003 | CA2451109A1 Infection control system |
| 01/23/2003 | CA2449504A1 Bridged bicyclic serine protease inhibitors |
| 01/22/2003 | EP1277759A1 Cytokine related treatments of disease |
| 01/22/2003 | EP1277750A1 Hydrates and crystals of a neuraminic acid compound |
| 01/22/2003 | EP1277471A1 Stable liquid preparation |
| 01/22/2003 | EP1277470A1 Injectable galenical formulation for use in photodynamic diagnostic or therapy and process of manufacturing it |
| 01/22/2003 | EP1276902A2 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 01/22/2003 | EP1276896A2 Method of identifying and producing antigen peptides and use thereof as vaccines |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276853A1 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 01/22/2003 | EP1276852A2 Viruses comprising mutated ion channel protein |